<DOC>
	<DOC>NCT01107964</DOC>
	<brief_summary>The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline, Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with lissamine green, and fluorescein tear break-up time) when compared to administration of placebo.</brief_summary>
	<brief_title>Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Age &gt; 18 years Typical symptoms of dry eye (photophobia, burning, foreign body sensation, blurred vision improved with blinking) Schirmer Test &lt; 8 mm/5 minutes Fluorescein tear breakup time &lt; 8 seconds No current use of dry eye treatment (except artificial lubrication) Signature on consent form Infectious keratoconjunctivitis or inflammatory disease unrelated to dry eye Eyelid or eyelash abnormalities Alteration of the nasolacrimal apparatus Treatment with drugs affecting tearing Concomitant ocular therapies Topical ophthalmic steroids taken during the 4 weeks before the study Pregnant/breastfeeding women History of liver disease History of fish and/or shellfish allergy or hypersensitivity History of corn allergy or hypersensitivity Treatment with systemic anticoagulation therapy Patients with bleeding disorders or those receiving anticoagulation (e.g., warfarin, enoxaparin, dipyridamole, clopidogrel)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Dry Eye Syndrome</keyword>
	<keyword>Recent Diagnosis of Dry Eye Syndrome</keyword>
</DOC>